THCA (Δ9-tetrahydrocannabinol), the most abundant non-psychoactive cannabinoid found in marijuana, has demonstrated its potent neuroprotective ability in a recent study.
Published in the British Journal of Pharmacology, the Spanish study conducted at Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), in Córdoba, Spain, found Δ9-THCA is a worthy treatment option for those suffering from debilitating neurodegenerative diseases.
Neurodegenerative Disorders and Δ9-THCA
According to the National Institutes of Health, neurodegenerative and neuroinflammatory diseases “result from the gradual and progressive loss of neural cells, leading to nervous system dysfunction.”
Unfortunately, these diseases affect more than 50 million Americans annually.
For the THCA study, “In vivo neuroprotective activity of Δ9-THCA was investigated in mice intoxicated with the mitochondrial toxin 3-nitropropionic acid (3-NP).”
The results of the study found “Cannabinoid acids bind and activate PPARγ with higher potency than their decarboxylated products. Δ9-THCA increases mitochondrial mass in neuroblastoma N2a cells, and prevents cytotoxicity induced by serum deprivation. Δ9-THCA, through a PPARγ-dependent pathway, was neuroprotectant in mice intoxicated with 3-NP, improving motor deficits and preventing striatal degeneration.”
The study concluded: “Δ9-THCA shows potent neuroprotective activity, worth consideration for the treatment of Huntington’s Disease and possibly other neurodegenerative and neuroinflammatory diseases. “